Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Thyroid Cancer
NCT02973997Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Feb 2018
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in differentiated thyroid cancer (DTC), sponsored by Academic and Community Cancer Research United. Primary endpoints: Complete Response Rate (Cohort 1) at 26 months and Confirmed Response Rate (Cohort 2) at 27 months. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02973997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973997.